Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial-Reference-Cited by-同舟云学术

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial

Published:2012-03 Issue:5 Volume:48 Page:721-727
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gross-Goupil M.,Fourcade A.,Blot E.,Penel N.,Négrier S.,Culine S.,Chaigneau L.,Lesimple T.,Priou F.,Lortholary A.,Kaminsky M.C.,Provencal J.,Voog E.,Bouzy J.,Laplanche A.,Fizazi K.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Cancer of unknown primary (CUP);Pavlidis;Crit Rev Oncol Hematol,2005

2. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP);Briasoulis;Ann Oncol,2005

3. Treatment for patients with unknown primary cancer and favorable prognostic factors;Hainsworth;Semin Oncol,2009

4. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma?;Lenzi;J Clin Oncol,1997

5. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site;Culine;J Clin Oncol,2002

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study;ESMO Open;2024-08

2. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary;Molecular Therapy;2024-07

3. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary;Clinical Chemistry;2024-01

4. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial;Nature Communications;2023-10-24

5. Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary;Frontiers in Oncology;2023-07-10